ArticleBMC clinical pathology2018
Primary hepatic neuroendocrine carcinoma: report of two cases and literature review.
Article in BMC clinical pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms.Nature communications · 2025Article
- Primary small cell-like hepatocellular carcinoma arising in a patient with fatty liver disease without cirrhosis: a case report and literature review.Gastroenterology report · 2025Article
- Primary hepatic neuroendocrine tumor with repeated diarrhea and flushing face: A case report and literature review.Heliyon · 2024Article
- Cystic presentation of primary hepatic neuroendocrine tumour: a case report with a brief review of literature.Exploration of targeted anti-tumor therapy · 2023Article
- Primary Hepatic Neuroendocrine Carcinoma : Amphicrine Type.The American surgeon · 2022Article
- Hepatectomy and pneumectomy combined with targeted therapy for primary hepatic neuroendocrine carcinoma: Case report and review of the literature.Frontiers in surgery · 2022Article
- Primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy: a case report.Surgical case reports · 2021Article
- A case of laparoscopic hepatectomy for a primary hepatic neuroendocrine tumor.Clinical journal of gastroenterology · 2021Article
- A case of primary hepatic mixed neuroendocrine-non-neuroendocrine tumor (MiNEN) associated with gallbladder carcinosarcoma.Clinical journal of gastroenterology · 2020Article
- Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- A primary hepatic neuroendocrine tumor disguised as hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2020Article
- Primary hepatic neuroendocrine tumors: A case report.Medicine · 2019Article
- Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm.World journal of gastrointestinal oncology · 2019Article
- Primary hepatic neuroendocrine tumours-Case series of a rare malignancy.International journal of surgery case reports · 2019Article
- Review
- Alpha-fetoprotein Secreting Neuroendocrine Carcinoma of the Liver: a Case Report and Literature Review.Journal of gastrointestinal cancer · 2018Article
- Primary Hepatic Neuroendocrine Carcinoma with Metastasis to the Mesentery: A Case Report.Case reports in oncologyArticle
- Hepatic neuroendocrine neoplasm: imaging patterns.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare. The diagnosis of PHNEC remains challenging-partly due to its rarity, and partly due to its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues. CASE PRESENTATION: We report two male PHNEC cases and discuss the diagnosis and treatment options. Both cases presented with abdominal pain; case two also presented with symptoms of jaundice. The initial diagnosis for both cases was poorly differentiated grade 3 small-cell neuroendocrine carcinoma, based on imaging characteristics and the pathology of liver biopsies. Final diagnoses of PHNEC were arrived at by ruling out non-hepatic origins. Case one presented with a large tumor in the right liver lobe, and the patient was treated with TACE. Case two presented with tumors in both liver lobes, invasions into the left branch of hepatic portal vein, and metastasis in the hepatic hilar lymph node. This patient was ineligible for TACE and was allergic to the somatostatin analogue octreotide. This limited treatment options to supportive therapies such as albumin supplementation for liver protection. Patient one and two died at 61 and 109 days, respectively, following initial hospital admission.
conclusionsWe diagnosed both cases with poorly differentiated grade 3 small-cell PHNEC through imaging characteristics, immunohistochemical staining of liver biopsies, and examinations to eliminate non-hepatic origins. Neither TACE nor liver protection appeared to significantly extend survival time of the two patients, suggesting these treatments may be inadequate to improve survival of patients with poorly differentiated grade 3 small-cell PHNEC. The prognosis of poorly differentiated grade 3 small-cell PHNEC is poor due to limited and ineffective treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.